Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study
Files
(Published version)
Date
2025
Authors
Cheung, E.C.L.
Adesuyan, M.
Szilcz, M.
Kalisch Ellett, L.M.
Shah, S.
Jani, Y.H.
Hägg, S.
Pratt, N.
Lau, K.K.
Luo, H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Age and Ageing, 2025; 54(5)
Statement of Responsibility
Conference Name
Abstract
<h4>Background</h4>Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) are first-line antihypertensive drugs for many patients, and influencing angiotensin systems may play a role in dementia risk. This study aimed to investigate whether exposure to different antihypertensive drug classes compared with ACEI affects the risk of dementia and pathological dementia subtypes in a large multinational database study.<h4>Methods</h4>This was a multinational population-based cohort study using electronic health databases in Hong Kong, the UK, Sweden and Australia. A common protocol was used to harmonise the study design. An active comparator, a new user design, was applied to compare the risk of all-cause dementia between different antihypertensive drug classes, with secondary outcomes of Alzheimer's disease (AD) and vascular dementia (VaD). Adjusted Cox proportional hazards models with inverse probability of treatment weighting were used to generate results in each study site and were pooled in meta-analysis.<h4>Results</h4>One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4 years. Compared to ACEI, initiation with ARB was associated with a reduced risk of incident all-cause dementia [hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.89-0.94] and VaD (HR 0.87, 95% CI 0.78-0.96) but not AD.<h4>Conclusions</h4>This is the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. When initiating antihypertensives, physicians and patients should consider the reduced risk of all-cause dementia and VaD with ARB compared with ACEI in their risk-benefit assessment.
School/Discipline
Dissertation Note
Provenance
Description
Data source: supplementary data, https://doi.org/10.1093/ageing/afaf121
Access Status
Rights
Copyright 2025 The Authors. (https://creativecommons.org/licenses/by-nc/4.0/)
Access Condition Notes: This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.